KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) EPS (Basic): 2009-2024

Historic EPS (Basic) for Regeneron Pharmaceuticals (REGN) over the last 16 years, with Dec 2024 value amounting to $40.90.

  • Regeneron Pharmaceuticals' EPS (Basic) rose 13.63% to $14.09 in Q3 2025 from the same period last year, while for Sep 2025 it was $43.45, marking a year-over-year increase of 0.49%. This contributed to the annual value of $40.90 for FY2024, which is 10.39% up from last year.
  • According to the latest figures from FY2024, Regeneron Pharmaceuticals' EPS (Basic) is $40.90, which was up 10.39% from $37.05 recorded in FY2023.
  • In the past 5 years, Regeneron Pharmaceuticals' EPS (Basic) registered a high of $76.40 during FY2021, and its lowest value of $32.65 during FY2020.
  • For the 3-year period, Regeneron Pharmaceuticals' EPS (Basic) averaged around $39.49, with its median value being $40.51 (2022).
  • Per our database at Business Quant, Regeneron Pharmaceuticals' EPS (Basic) skyrocketed by 134.00% in 2021 and then tumbled by 46.98% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' EPS (Basic) (Yearly) stood at $32.65 in 2020, then skyrocketed by 134.00% to $76.40 in 2021, then slumped by 46.98% to $40.51 in 2022, then dropped by 8.54% to $37.05 in 2023, then climbed by 10.39% to $40.90 in 2024.